142155-43-9

Usage

InChI:InChI=1/C15H21N3O/c1-17(2)11-12-19-15(13-7-5-4-6-8-13)14-9-10-16-18(14)3/h4-10,15H,11-12H2,1-3H3/t15-/m1/s1

Upstream product

• 2498-25-1 2-(N,N-dimethylamino)ethanol hydrochloride 
• 148408-72-4 (R)-(+)-1-Methyl-α-phenyl-1H-pyrazole-5-methanol 
• 4584-46-7 (2-chloroethyl)dimethylamine hydrochloride 
• 32500-65-5 1-methyl-5-(1'-hydroxy-1'phenylmethyl)pyrazole 
• 13292-87-0 dimethyl sulfide borane 
• 61496-24-0 (1-methyl-1H-pyrazol-5-yl)(phenyl)methanone 

Relevant academic research and scientific papers

1-METHYLPYRAZOLE MODULATORS OF SUBSTANCE P, CALCITONIN GENE-RELATED PEPTIDE, ADRENERGIC RECEPTOR, AND/OR 5-HT RECEPTOR

The present invention relates to new 1-methylpyrazole modulators of substance P release, calcitonin gene-related peptide activity, adrenergic receptor activity, and/or 5 -HT receptor activity, pharmaceutical compositions thereof, and methods of use thereof.

Derivatives of aryl (or heteroaryl) azolylcarbinoles for the treatment of urinary incontinence

Derivatives of aryl(or heteroaryl)azolylcarbinols of general formula (I), in which Ar represents a phenyl radical or a thienyl radical, optionally substituted, R1 represents a hydrogen atom or a lower alkyl group, R2 represents a dialkylaminoalkyl or azaheterocylclylalkyl and Het represents an azole unsubstituted or optionally substituted by one or two substituents, and their physiologically acceptable salts; are useful as drugs in human and/or veterinary therapeutics to treat urinary incontinence in mammals, including man.

Utilization of aryl(or heteroaryl)azolylcarbinol derivatives in the preparation of a medicament for the treatment of troubles mediated by an excess of substance P

The present invention relates to the use of derivatives of aryl (or heteroaryl) azolylcarbinols of general formula (1) of the specification, as well as their physiologically acceptable salts, in the manufacture of medicaments, useful in human and/or veterinary therapy, for the treatment of disorders that are mediated by an excess of substance P, and especially disorders of the central nervous system such as anxiety, depression, schizophrenia, manic depressive psychosis, sexual dysfunction, drug addiction, cognitive disorders, and locomotive disorders.

UTILIZATION OF ARYL(OR HETEROARYL)AZOLYLCARBINOL DERIVATIVES IN THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT OF NEUROGENIC INFLAMMATION

The derivatives of aryl(or heteroaryl)azolylcarbinol (I), in which R1 is an atom of hydrogen or a lower alkyl group; R2 is a dialkylaminoalkyl or azaheterocyclylalkyl radical; Ar is a phenyl or thienyl radical, optionally substituted; and Het is a heterocyclic five-membered azotic aromatic ring that contains from one to three nitrogen atoms, optionally substituted, are suitable for the treatment of neurogenic inflammation, present in different processes, such as diabetes, asthma, cystitis, gingivitis, migraine, dermatitis, rhinitis, psoriasis, inflammation of sciatic and lumbar nerves, gastrointestinal processes, ocular inflammation, etc., in mammals, including man.

Process for obtaining enantiomers of cis-olirtine

PCT No. PCT/ES98/00223 Sec. 371 Date Feb. 1, 2000 Sec. 102(e) Date Feb. 1, 2000 PCT Filed Jul. 31, 1998 PCT Pub. No. WO99/07684 PCT Pub. Date Feb. 18, 1999The procedure comprises (a) the enantioselective reduction of a pro-chiral ketone (III) by using a r

Enantioselective synthesis of (R)- and (S)-cizolirtine; application of oxazaborolidine-catalyzed asymmetric borane reduction to azolyl phenyl ketones

An efficient enantioselective synthesis of (R)- and (S)cizolirtine 1 is described. The key step of the procedure is the CBS-oxazaborolidine asymmetric reduction of phenyl pyrazolyl ketone 2. Related enantioselective reductions of several azolyl phenyl ketones are also reported.